Article
Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD): Consensus on Obesity and Cardiometabolic Comorbidities in Inflammatory Bowel Disease using Evidence Synthesis and the RAND/UCLA Appropriateness Method
2025-12-22
Abstract excerpt
<h4>Introduction</h4> Obesity and related cardiometabolic comorbidities, including hypertension, dyslipidemia, diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and atherosclerotic cardiovascular disease (ASCVD), are increasingly prevalent among individuals with inflammatory bowel disease (IBD). These conditions influence disease activity, therapeutic response, surgical outcomes, and ove...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- aa438cff-4bdb-56fa-b883-1506c4c8ab6b
- DOI
- 10.64898/2025.12.20.25342738
